Major Depressive Disorder (DSM-V) – Special Topics – Special Topics: Comorbidities in Major Depressive Disorder (US)
Psychiatric disorders such as anxiety, posttraumatic stress disorder (PTSD), and insomnia frequently coexist with major depressive disorder (MDD) and present treatment challenges to psychiatrists and primary care physicians (PCPs). Although some antidepressants are effective in managing MDD as well as a comorbid condition (e.g., selective serotonin reuptake inhibitors for MDD patients with comorbid anxiety), not all drug-treated patients fully respond to treatment. Treatment of MDD with a comorbid disorder presents opportunities for drug development and areas of clinical differentiation from existing antidepressants. Of note, Biogen / Sage Therapeutics’ zuranolone has shown efficacy in its late-phase studies in reducing elevated anxiety in MDD patients. Janssen’s seltorexant could be beneficial treating MDD patients with comorbid insomnia symptoms. The expected FDA approval of Lundbeck / Otsuka’s Rexulti for PTSD could encourage physicians to prescribe the drug for MDD with comorbid PTSD. These therapies have the potential to alter treatment pathways for MDD patients with comorbid conditions.
QUESTIONS ANSWERED
- Which comorbid disorders are most common in MDD patients? How do physicians treat MDD patients with comorbid anxiety, PTSD, or insomnia?
- What factors most influence physicians’ choice of a pharmacotherapy for MDD patients with comorbid anxiety, PTSD, or insomnia?
- Which drug attributes should be at the forefront in the development of therapies to treat MDD patients with comorbid anxiety, PTSD, or insomnia?
- What are the physician-perceived advantages and disadvantages of zuranolone for managing MDD patients with a comorbid anxiety disorder and of seltorexant for managing MDD patients with comorbid insomnia? Where would these drugs, if launched, fit in the treatment algorithm for MDD patients with the respective comorbid disorder?
- How would Rexulti’s additional FDA approval for PTSD impact physician prescribing of the drug to their MDD patients with comorbid PTSD?
PRODUCT DESCRIPTION
Clarivate’s Special Topics reports assess key trends in dynamic disease areas. This report on comorbidities in MDD will help drug marketers and developers gain needed insight on physician-reported treatment dynamics, prescribing behavior, key challenges managing MDD patients with comorbidities such as anxiety disorder, PTSD, and insomnia, most important attributes for emerging therapies for these comorbid disorders, and physician perceptions of select emerging therapies that would benefit MDD patients with these comorbidities.
CONTENT HIGHLIGHTS
Geographies: United States.
Primary research: Survey of 101 U.S. psychiatrists and PCPs.
Key drugs covered: Zuranolone (SAGE-217), Rexulti, seltorexant (JNJ-42847922), SSRIs, SNRIs, mixed serotonin modulators, atypical antipsychotics, NMDA receptor antagonists, mood stabilizers, benzodiazepines, nonbenzodiazepine sedative-hypnotics, etc.
Key insights provided:
- Patient characteristics.
- Physician treatment practices and physician insights on medical practice.
- Most important attributes for emerging therapies.
- Anticipated use of emerging therapies.
Himanshu Jain, M.S.(Pharm.), Senior Manager, CNS and Ophthalmology. He has authored content for psychiatry and ophthalmology indications, including forecasting markets for schizophrenia, depression, and dry eye disease. He has about 15 years of experience working in market research and consulting firms. He earned his master’s degree in Pharmacology & Toxicology from the National Institute of Pharmaceutical Education and Research and holds an Executive Post-Graduate Diploma in International Business from the Indian Institute of Foreign Trade.
Soumya Soni, M.Tech., Healthcare Research & Data Analyst, CNS and Ophthalmology. Ms. Soni has substantial experience in market research, competitive intelligence, promotional intelligence, and consulting. She has produced multiple competitive intelligence-based landscape reports in oncology and contributed to ad-hoc market research projects. She also has experience in post-conference report preparation for key medical conferences such as AACR, ESMO, SITC, and ASH. Ms. Soni holds a master’s degree in biotechnology from Jaypee Institute of Information Technology in Noida, India.